Effective treatment of hereditary haemochromatosis with desferrioxamine in selected cases
- 19 November 2003
- journal article
- case report
- Published by Wiley in British Journal of Haematology
- Vol. 123 (5) , 952-953
- https://doi.org/10.1046/j.1365-2141.2003.04708.x
Abstract
The treatment of iron overload by s.c. desferrioxamine (DFO) was studied in three patients with hereditary haemochromatosis in which phlebotomy treatment was not, or transiently not, possible because of their serious clinical condition or the lack of appropriate peripheral veins. Repeated non-invasive liver iron concentration measurements by superconducting quantum interference device biosusceptometry showed that DFO treatment (2 g/d for 9-11 months) was as effective (liver iron elimination rate: 12 mg/d) as normal phlebotomy treatment (5.9 or 14.3 mg/d respectively) with weekly 500-ml blood removals. This demonstrates that DFO is an effective alternative therapy for haemochromatosis when phlebotomy is not possible.Keywords
This publication has 6 references indexed in Scilit:
- Non-Invasive Liver Iron Quantification by SQUID-Biosusceptometry and Serum Ferritin Iron as New Diagnostic Parameters in Hereditary HemochromatosisBlood Cells, Molecules, and Diseases, 2002
- EASL International Consensus Conference on HaemochromatosisJournal of Hepatology, 2000
- Management of HemochromatosisAnnals of Internal Medicine, 1998
- A novel MHC class I–like gene is mutated in patients with hereditary haemochromatosisNature Genetics, 1996
- GENETICS IN MEDICINEThe Lancet Healthy Longevity, 1967
- The Treatment of Haemochromatosis with DesferrioxamineActa Haematologica, 1963